Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Merck
Scientific Title
Study of Pembrolizumab (MK-3475) plus Enalutamide versus placebo plus Enzalutamide in participants with metastatic castraion-resistant prostate cancer (mCRPC)